Compositions and methods for improving persistence of cells for adoptive transfer
AssigneeCelyad S.A.
InventorsDavid GILHAM, Simon BORNSCHEIN, Susanna RAITANO
Life of this patent
Estimating the term…
Abstract
The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy. Provided herein are compositions and methods for improving in vivo persistence of cells intended for adoptive transfer. This is achieved by making the cells less vulnerable to clearance caused by NK cells of the subject receiving the adoptive cell therapy.
Claims14
An engineered immune cell comprising an exogenous nucleic acid molecule and at least one of:
- One or more endogenous genes encoding a NKG2D ligand that have been engineered to be inactivated;
- One or more inhibitors directed against one or more NKG2D ligands.
A method of rendering an immune cell less sensitive to clearance by NK cells comprising the inhibition of one or more NKG2D ligands in the immune cell.
Dependencies are inferred from the claim text.